非酒精性脂肪性肝病临床指南和共识的质量评价及推荐意见比较研究

doi:10.12114/j.issn.1007-9572.2022.0835

中国全科医学 ›› 2023, Vol. 26 ›› Issue (20): 2439-2446.DOI: 10.12114/j.issn.1007-9572.2022.0835

所属专题：指南/共识最新文章合集；消化系统疾病最新文章合集；全科质控专项研究

• 指南·共识 • 下一篇

非酒精性脂肪性肝病临床指南和共识的质量评价及推荐意见比较研究

张卓然¹, 于长禾¹, 安易¹, 何新¹, 郭一¹, 邓金燕¹, 李悦¹, 韩登¹, 皮珊珊¹, 贺俊芝², 陈玥¹, 叶永安¹^,³, 杜宏波¹^,³^,^*()

1．100700　北京市，北京中医药大学东直门医院
2．412000　湖南省株洲市，湖南省直中医医院
3．100700　北京市，北京中医药大学肝病研究院

收稿日期:2022-11-03 修回日期:2023-01-30 出版日期:2023-07-15 发布日期:2023-02-23
通讯作者: 杜宏波
作者贡献：张卓然负责提出研究选题方向和撰写文章初稿；于长禾负责研究方法的设计；安易、何新负责文献的检索和资料提取；邓金燕、李悦负责数据统计；韩登、皮珊珊负责图表的制作；贺俊芝、陈玥负责数据和图表的核对；叶永安、杜宏波、郭一负责文章的修改和审校；杜宏波对文章整体负责。
基金资助:
国家自然科学基金青年科学基金项目(81904138); 全国中医临床优秀人才研修项目(国中医药人教函[2022]-1)

Quality Assessment and Recommendations of Clinical Guidelines and Consensuses on Non-alcoholic Fatty Liver Disease: a Comparative Study

ZHANG Zhuoran¹, YU Changhe¹, AN Yi¹, HE Xin¹, GUO Yi¹, DENG Jinyan¹, LI Yue¹, HAN Deng¹, PI Shanshan¹, HE Junzhi², CHEN Yue¹, YE Yong'an¹^,³, DU Hongbo¹^,³^,^*()

1. Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China
2. Hunan Province Directly Affiliated TCM Hospital, Zhuzhou 412000, China
3. Hepatology Disease Research Institute, Beijing University of Traditional Chinese Medicine, Beijing 100700, China

Received:2022-11-03 Revised:2023-01-30 Published:2023-07-15 Online:2023-02-23
Contact: DU Hongbo

分享到

1. 2023中国知网《学术精要数据库》论文入选证书.png(618KB)

摘要/Abstract

摘要： 背景非酒精性脂肪性肝病（NAFLD）是消化系统的常见疾病。随着生活水平的提高和病毒性肝炎研究的不断突破，NAFLD已取代病毒性肝炎，成为常见的慢性肝病。指南性文件能够为临床工作人员提供标准可靠的诊疗方法，筛选和制定高质量的指南性文件对规范NAFLD的临床实践具有十分重要的意义。目的分析NAFLD指南性文件的方法学质量和报告质量，并对推荐意见进行总结和比较，为未来NAFLD指南的制订及报告提供参考依据。方法计算机检索PubMed、中国知网（CNKI）、中国生物医学文献数据库（CBM）、万方数据知识服务平台和维普网数据库，并补充检索WHO、国际指南协作网（GIN）、英国国家临床优化研究所（NICE）、美国国立指南文库（NGC）、苏格兰院际间协作网（SIGN）、医脉通数据库（Medlive）等数据库中有关NAFLD的临床实践指南和共识，检索时限为2012-01-01—2022-01-01。由2名肝病领域研究人员筛选文献、提取资料并分别独立使用AGREEⅡ和RIGHT对纳入指南性文件的方法学质量和报告质量进行评价，并对较高质量指南性文件的推荐意见进行整理和比较。结果共纳入19篇文献，其中12篇指南、7篇共识；中文6篇、英文13篇；使用循证方法制订10篇。AGREEⅡ各领域平均得分分别为：范围与目的（42.84%）、参与人员（31.43%）、严谨性（31.25%）、清晰性（60.67%）、应用性（32.68%）、独立性（37.50%）。RIGHT各领域平均得分分别为：基本信息（59.65%）、背景（66.12%）、证据（42.11%）、推荐意见（39.85%）、评审和质量保证（17.11%）、资金资助与利益冲突声明和管理（18.42%）、其他方面（47.37%）。基于循证方法制订的指南性文件在AGREEⅡ的平均得分及RIGHT中的报告质量均高于非循证指南性文件；国外指南性文件在AGREEⅡ的平均得分及RIGHT中的报告质量均高于国内指南性文件。主要推荐意见涉及筛查与诊断、评估、管理（非药物治疗和药物治疗）以及手术治疗。结论目前已发表的NAFLD指南性文件的方法学质量及报告质量仍有待提升，国内指南性文件较国际仍有差距，中医指南性文件的制订应遵循循证方法。在指南制订和报告过程中，应进一步参考AGREEⅡ和RIGHT等国际标准。临床应提高对NAFLD高危人群的筛查意识，建立完善的早期无创诊断和评估体系，并向NAFLD患者提供针对生活方式、肝脏功能、代谢障碍的多维度治疗方案。

关键词: 非酒精性脂肪性肝病, AGREEⅡ, RIGHT, 指南, 共识, 方法学质量, 推荐意见

Abstract:

Background

Non-alcoholic fatty liver disease (NAFLD) is a common disease of the digestive system. With the improvements of living standards and breakthroughs in viral hepatitis research, NAFLD has replaced viral hepatitis as the most common chronic liver disease. Guidance documents can provide clinical staff with standard and reliable diagnosis and treatment approaches. The screening and development of high-quality guidance documents is of great importance to standardise the clinical practice of NAFLD.

Objective

To analyze the methodological quality and reporting quality of guidance documents for NAFLD, summarize and compare the recommendations, so as to provide a reference for the development and report of future guidelines for NAFLD.

Methods

PubMed, CNKI, CBM, Wanfang Data Knowledge Service Platform, VIP Database were searched for clinical guidelines and consensuses on NAFLD supplemented by WHO, GIN, NICE, SIGN and Medlive from 2012-01-01 to 2022-01-01. Two researchers in the field of liver disease screened the literature, extracted the data and independently evaluated the methodological quality and reporting quality of the included guideline documents using AGREE Ⅱ and RIGHT, respectively. The recommendations of the higher quality guideline documents were collated and compared by the two researchers.

Results

A total of 19 publications were enrolled, including 12 guidelines and 7 consensuses; 6 in Chinese and 13 in English; 10 of which were developed using an evidence-based approach. The average scores for each domain of AGREE Ⅱ were 42.84% for scope and purpose, 31.43% for participants, 31.25% for rigour, 60.67% for clarity, 32.68% for application and 37.50% for independence. The average scores of RIGHT in each area were 59.65% for basic information, 66.12% for background, 42.11% for evidence, 39.85% for recommendations, 17.11% for review and quality assurance, 18.42% for funding and conflict of interest statement and management, 47.37% for other aspects. The average scores in AGREEⅡ and reporting qualities in RIGHT of evidence-based guidance documents were both higher than non-evidence-based guidance documents. The average scores in AGREEⅡ and reporting qualities in RIGHT of foreign guidance documents were higher than domestic guidance documents. The main recommendations relate to screening and diagnosis, assessment, management (non-pharmacologic and pharmacologic treatment) and surgical treatment.

Conclusion

The methodological quality and reporting quality of the published guidance documents for NAFLD still need to be improved, and there are still gaps between domestic guidance documents and international guidance documents. The development of TCM guidance documents should follow an evidence-based approach. Further reference should be made to international standards such as AGREE Ⅱ and RIGHT in the development and reporting of guidelines. Clinical screening awareness for high-risk population of NAFLD and a comprehensive system for early non-invasive diagnosis and assessment should be established. Multidimensional treatment plans for lifestyle, liver function and metabolic disorders should be provided for patients with NAFLD.

Key words: Non-alcoholic fatty liver disease, AGREEⅡ, RIGHT, Guidelines, Consensus, Methodological quality, Recommendation

张卓然,于长禾,安易,等. 非酒精性脂肪性肝病临床指南和共识的质量评价及推荐意见比较研究[J]. 中国全科医学, 2023, 26(20): 2439-2446. DOI: 10.12114/j.issn.1007-9572.2022.0835.
ZHANG Zhuoran,YU Changhe,AN Yi, et al. Quality Assessment and Recommendations of Clinical Guidelines and Consensuses on Non-alcoholic Fatty Liver Disease: a Comparative Study[J]. Chinese General Practice, 2023, 26(20): 2439-2446. DOI: 10.12114/j.issn.1007-9572.2022.0835.

图/表 1

参考文献 41

[1]	LI W H, ALAZAWI W. Non-alcoholic fatty liver disease[J]. Clin Med （Lond），2020，20(5):509-512. DOI：10.7861/clinmed.2020-0696.
[2]	ESLAM M, NEWSOME P N, SARIN S K，et al. A new definition for metabolic dysfunction-associated fatty liver disease：an international expert consensus statement[J]. J Hepatol，2020，73(1):202-209. DOI：10.1016/j.jhep.2020.03.039.
[3]	MAURICE J, MANOUSOU P. Non-alcoholic fatty liver disease[J]. Clin Med，2018，18(3):245-250. DOI：10.7861/clinmedicine.18-3-245.
[4]	丁雪娇，赵双清，李雅丽. 非酒精性脂肪性肝病的流行病学及防治[J]. 中国临床保健杂志，2021，24(6):742-746. DOI：10.3969/J.issn.1672-6790.2021.06.005.
[5]	YOUNOSSI Z M, KOENIG A B, ABDELATIF D，et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence，incidence，and outcomes[J]. Hepatology，2016，64(1):73-84. DOI：10.1002/hep.28431.
[6]	舒筠然，李俊琪，刘琼. 非酒精性脂肪性肝病的流行病学和危险因素分析[J]. 临床肝胆病杂志，2019，35(9):2085-2090. DOI：10.3969/j.issn.1001-5256.2019.09.045.
[7]	BROUWERS M C, KHO M E, BROWMAN G P，et al. AGREE Ⅱ：advancing guideline development，reporting，and evaluation in health care[J]. Prev Med，2010，51(5):421-424. DOI：10.1016/j.ypmed.2010.08.005.
[8]	CHEN Y L, YANG K H, MARUŠIC A，et al. A reporting tool for practice guidelines in health care：the RIGHT statement[J]. Ann Intern Med，2017，166(2):128-132. DOI：10.7326/M16-1565.
[9]	鞠春晓，张瑶，刘晓林，等. 慢性心力衰竭防治指南和共识的方法学质量评价[J]. 中国循证医学杂志，2021，21(9):1091-1097.
[10]	中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南（2018更新版）[J]. 中华肝脏病杂志，2018，26(3):195-203. DOI：10.3760/cma.j.issn.1007-3418.2018.03.008.
[11]	中华医学会内分泌学分会. 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识（第二版）[J]. 临床肝胆病杂志，2018，34(10):2103-2108. DOI：10.3969/j.issn.1001-5256.2018.10.010.
[12]	李军祥，陈誩，王允亮. 非酒精性脂肪性肝病中西医结合诊疗共识意见（2017年）[J]. 中国中西医结合消化杂志，2017，25(11):805-811.
[13]	中华中医药学会脾胃病分会. 非酒精性脂肪性肝病中医诊疗指南（基层医生版）[J]. 中西医结合肝病杂志，2019，29(5):483-486.
[14]	张声生，李军祥. 非酒精性脂肪性肝病中医诊疗专家共识意见（2017）[J]. 临床肝胆病杂志，2017，33(12):2270-2274.
[15]	中华医学会内分泌学分会，中华医学会糖尿病学分会. 中国成人2型糖尿病合并非酒精性脂肪性肝病管理专家共识[J]. 中华内分泌代谢杂志，2021，37(7):589-598.
[16]	National Guideline Centre（UK）. Non-alcoholic fatty liver disease：assessment and management[R]. London：National Institute for Health and Care Excellence （NICE），2016.
[17]	Associazione Italiana per lo Studio del Fegato（AISF）, Società Italiana di Diabetologia（SID） and Società Italiana dell'Obesità（SIO）. Non-alcoholic fatty liver disease in adults 2021：a clinical practice guideline of the Italian Association for the Study of the Liver （AISF），the Italian Society of Diabetology （SID） and the Italian Society of Obesity （SIO）[J]. Eat Weight Disord，2022，27(5):1603-1619. DOI：10.1007/s40519-021-01287-1.
[18]	KANG S H, LEE H W, YOO J J，et al. KASL clinical practice guidelines：management of nonalcoholic fatty liver disease[J]. Clin Mol Hepatol，2021，27(3):363-401. DOI：10.3350/cmh.2021.0178.
[19]	FOUAD Y, ESMAT G, ELWAKIL R，et al. The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Saudi J Gastroenterol，2022，28(1):3-20. DOI：10.4103/sjg.sjg_357_21.
[20]	FRANCQUE S, LANTHIER N, VERBEKE L，et al. The Belgian association for study of the liver guidance document on the management of adult and paediatric non-alcoholic fatty liver disease[J]. Acta Gastroenterol Belg，2018，81(1):55-81.
[21]	Recommendations of the Polish Group of Experts for Non-alcoholic Fatty Liver Disease （PGE-NAFLD）, TOMASIEWICZ K, FLISIAK R，et al. Recommendations for the management of non-alcoholic fatty liver disease （NAFLD）[J]. Clin Exp Hepatol，2018，4(3):153-157. DOI：10.5114/ceh.2018.78118.
[22]	COTRIM H P, PARISE E R, FIGUEIREDO-MENDES C，et al. Nonalcoholic fatty liver disease Brazilian society of hepatology consensus[J]. Arq Gastroenterol，2016，53(2):118-122. DOI：10.1590/S0004-28032016000200013.
[23]	ALSWAT K A, FALLATAH H I, AL-JUDAIBI B，et al. Position statement on the diagnosis and management of non-alcoholic fatty liver disease[J]. Saudi Med J，2019，40(6):531-540. DOI：10.15537/smj.2019.6.23980.
[24]	ARAB J P, DIRCHWOLF M, ÁLVARES-DA-SILVA M R，et al. Latin American Association for the study of the liver （ALEH） practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease[J]. Ann Hepatol，2020，19(6):674-690. DOI：10.1016/j.aohep.2020.09.006.
[25]	CHAN W K, TAN S S, CHAN S P，et al. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease[J]. J Gastroenterol Hepatol，2022，37(5):795-811. DOI：10.1111/jgh.15787.
[26]	ESLAM M, SARIN S K, WONG V W S，et al. The Asian Pacific Association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int，2020，14(6):889-919. DOI：10.1007/s12072-020-10094-2.
[27]	REVIEW TEAM, LABRECQUE D R, ABBAS Z，et al. World Gastroenterology Organisation global guidelines：nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. J Clin Gastroenterol，2014，48(6):467-473. DOI：10.1097/MCG.0000000000000116.
[28]	CHALASANI N, YOUNOSSI Z, LAVINE J E，et al. The diagnosis and management of non-alcoholic fatty liver disease：practice guideline by the American Association for the Study of Liver Diseases，American College of Gastroenterology，and the American Gastroenterological Association[J]. Am J Gastroenterol，2012，107(6):811-826. DOI：10.1038/ajg.2012.128.
[29]	靳睿，王晓晓，刘峰，等. 非酒精性脂肪性肝病的药物治疗进展[J]. 临床肝胆病杂志，2022，38(7):1634-1640. DOI：10.3969/j.issn.1001-5256.2022.07.033.
[30]	胡中杰，张晶. 我国非酒精性脂肪性肝病的研究现状[J]. 临床肝胆病杂志，2016，32(3):552-556. DOI：10.3969/j.issn.1001-5256.2016.03.034.
[31]	BURGERS J S, GROL R, KLAZINGA N S，et al. Towards evidence-based clinical practice：an international survey of 18 clinical guideline programs[J]. Int J Qual Health Care，2003，15(1):31-45. DOI：10.1093/intqhc/15.1.31.
[32]	MA X F, LIU S S, ZHANG J，et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients：a systematic review and meta-analysis[J]. BMC Gastroenterol，2020，20(1):10. DOI：10.1186/s12876-020-1165-z.
[33]	AMERNIA B, MOOSAVY S H, BANOOKH F，et al. FIB-4，APRI，and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas，Iran[J]. BMC Gastroenterol，2021，21(1):453. DOI：10.1186/s12876-021-02038-3.
[34]	SCRAGG J, HALLSWORTH K, TAYLOR G，et al. Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease[J]. BMJ Open Gastroenterol，2021，8(1):e000678. DOI：10.1136/bmjgast-2021-000678.
[35]	WATANABE M, TOZZI R, RISI R，et al. Beneficial effects of the ketogenic diet on nonalcoholic fatty liver disease：a comprehensive review of the literature[J]. Obes Rev，2020，21(8):e13024. DOI：10.1111/obr.13024.
[36]	CUNHA G M, GUZMAN G, CORREA DE MELLO L L，et al. Efficacy of a 2-month very low-calorie ketogenic diet （VLCKD） compared to a standard low-calorie diet in reducing visceral and liver fat accumulation in patients with obesity[J]. Front Endocrinol （Lausanne），2020，11:607. DOI：10.3389/fendo.2020.00607.
[37]	MANSOUR A, MOHAJERI-TEHRANI M R, SAMADI M，et al. Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic，metabolic，and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes：a randomized，double-blind，placebo-controlled，clinical trial[J]. Nutr J，2021，20(1):35. DOI：10.1186/s12937-021-00694-5.
[38]	SEGHIERI M, CHRISTENSEN A S, ANDERSEN A，et al. Future perspectives on GLP-1 receptor agonists and GLP-1/glucagon receptor Co-agonists in the treatment of NAFLD[J]. Front Endocrinol （Lausanne），2018，9:649. DOI：10.3389/fendo.2018.00649.
[39]	O'DONOGHUE M L, FAZIO S, GIUGLIANO R P，et al. Lipoprotein（a），PCSK9 inhibition，and cardiovascular risk[J]. Circulation，2019，139(12):1483-1492. DOI：10.1161/CIRCULATIONAHA.118.037184.
[40]	WU Y R, SHI X Y, MA C Y，et al. Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway[J]. Cardiovasc Diabetol，2019，18(1):146. DOI：10.1186/s12933-019-0954-6.
[41]	DAY C P, JAMES O F. Steatohepatitis：a tale of two hits?[J]. Gastroenterology，1998，114(4):842-845. DOI：10.1016/s0016-5085(98)70599-2.

非酒精性脂肪性肝病临床指南和共识的质量评价及推荐意见比较研究

Quality Assessment and Recommendations of Clinical Guidelines and Consensuses on Non-alcoholic Fatty Liver Disease: a Comparative Study

RichHTML

PDF

补充材料

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 41

相关文章 15

编辑推荐

Metrics

留言

[1]	张娜文, 黄少敏, 田利民. 成人血清骨钙素水平与非酒精性脂肪性肝病发生风险的Meta分析[J]. 中国全科医学, 2024, 27(12): 1519-1524.
[2]	史威力, 李明艳, 段红艳. 《他汀类药物用于成年人心血管疾病的一级预防：美国预防临床服务指南工作组推荐声明》解读[J]. 中国全科医学, 2024, 27(12): 1405-1412.
[3]	曾凌枫, 张慧, 雷思, 卓慧, 叶云, 许琰, 罗荧荃. 《成年人阻塞性睡眠呼吸暂停低通气综合征筛查：美国预防临床服务指南工作组推荐声明》解读[J]. 中国全科医学, 2024, 27(12): 1412-1416.
[4]	李明艳, 史威力, 段红艳. 阿司匹林用于成年人心血管疾病的一级预防：美国预防临床服务指南工作组推荐声明解读[J]. 中国全科医学, 2024, 27(11): 1277-1282.
[5]	李迎晨, 赵明芳, 吴瑛. 《肺癌筛查：美国预防临床服务指南工作组推荐声明》现状与最新指南解读[J]. 中国全科医学, 2024, 27(11): 1283-1287.
[6]	《中国全科医学》定性和混合方法研究质量评价小组. 2021年中国基层卫生和全科医学研究方法学质量评价报告：定性研究和混合方法研究部分[J]. 中国全科医学, 2024, 27(10): 1173-1178.
[7]	《中国全科医学》定量研究、系统综述和指南/共识质量评价小组. 2021年中国基层卫生和全科医学方法学质量评价报告：定量研究、系统综述和指南/共识部分[J]. 中国全科医学, 2024, 27(07): 773-783.
[8]	谭惠文, 李丹婷, 余叶蓉. 垂体催乳素瘤的临床特点及诊治要点更新——基于《2022版ICCE/AME垂体催乳素瘤临床实践共识》解读[J]. 中国全科医学, 2024, 27(06): 650-655.
[9]	贾丽燕, 赵能江, 闫冰, 张智海, 占娜, 林远冰, 刘建平, 杨叔禹. 基层医师对糖尿病中医类指南知悉程度与使用现状的影响因素研究[J]. 中国全科医学, 2024, 27(05): 589-596.
[10]	中华医学会心身医学分会进食障碍协作学组, 中华医学会精神医学分会进食障碍研究协作组, 陈涵, 陈妍, 韩慧琴, 李雪霓, 张岚, 孔庆梅, 乔慧芬, 匡桂芳, 孙建琴, 虞阳, 金富锐, 蒋晶晶, 张大荣, 栗克清, 王振, 陈珏. 中国神经性厌食症诊疗专家共识[J]. 中国全科医学, 2024, 27(05): 509-520.
[11]	中国睡眠研究会. 失眠数字疗法中国专家共识[J]. 中国全科医学, 2024, 27(04): 381-390.
[12]	中华医学会心身医学分会, 中国康复医学会心血管病预防与康复专委会, 丁荣晶, 刘园园, 袁丽霞, 王一波, 李忠艳. 双心门诊建设规范中国专家共识[J]. 中国全科医学, 2024, 27(03): 253-261.
[13]	中华医学会心身医学分会整体健康协作学组. 精神性头晕诊疗中国专家共识[J]. 中国全科医学, 2024, 27(02): 125-131.
[14]	窦紫岩, 钱文红, 孔邻润, 陈晔, 李明亮, 张静波. 非酒精性脂肪性肝病检出率现状及其影响因素：基于北京市32万人群数据[J]. 中国全科医学, 2024, 27(02): 144-149.
[15]	Searle Kendall, Blashki Grant, Kakuma Ritsuko, 杨辉, 吕淑荣, 李宝琪, 肖莹莹, Minas Harry. 将WHO《心理健康差距干预指南》应用于中国全科医学服务：一项德尔菲研究[J]. 中国全科医学, 2024, 27(01): 15-26.